[
  {
    "qas": [
      {
        "answers": [
          {
            "text": "SUPPLY AGREEMENT",
            "answer_start": 14
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Document Name",
        "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Ultragenyx",
            "answer_start": 158
          },
          {
            "text": "CREMER OLEO GmbH & Co KG",
            "answer_start": 41
          },
          {
            "text": "Cremer",
            "answer_start": 143
          },
          {
            "text": "Ultragenyx Pharmaceutical Inc",
            "answer_start": 158
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Parties",
        "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "November 19t h, 2012",
            "answer_start": 13733
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Agreement Date",
        "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Effective Date",
        "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective\u00a0",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "This Agreement shall become effective on the date of its execution and shall remain in force for three years (the \"Initial Term\").",
            "answer_start": 9392
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Expiration Date",
        "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Thereafter, the Agreement shall be automatically renewed for additional two year periods (each a \"Renewal Term\", the Initial Term and all Renewal Terms, the \"Term\") unless either Party notifies the other Party of its intention not to renew in writing at least three calendar months before the expiration of the then current Term.",
            "answer_start": 9523
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Renewal Term",
        "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Thereafter, the Agreement shall be automatically renewed for additional two year periods (each a \"Renewal Term\", the Initial Term and all Renewal Terms, the \"Term\") unless either Party notifies the other Party of its intention not to renew in writing at least three calendar months before the expiration of the then current Term.",
            "answer_start": 9523
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Notice Period To Terminate Renewal",
        "question": "Highlight the parts (if any) of this contract related to \"Notice Period To Terminate Renewal\" that should be reviewed by a lawyer. Details: What is the notice period required to terminate renewal?",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "The laws of the Federal Republic of Germany shall apply to the Agreement and any legal relations thereof, especially any purchase order, between Cremer and Ultragenyx shall be governed by that law.",
            "answer_start": 11656
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Governing Law",
        "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Most Favored Nation",
        "question": "Highlight the parts (if any) of this contract related to \"Most Favored Nation\" that should be reviewed by a lawyer. Details: Is there a clause that if a third party gets better terms on the licensing or sale of technology/goods/services described in the contract, the buyer of such technology/goods/services under the contract shall be entitled to those better terms?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Non-Compete",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?\u00a0",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Cremer shall supply Ultragenyx exclusively with the Product worldwide",
            "answer_start": 1603
          },
          {
            "text": "Ultragenyx shall purchase the Product exclusively from Cremer.",
            "answer_start": 1824
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Exclusivity",
        "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing\u00a0 commitment with the counterparty? This includes a commitment to procure all \u201crequirements\u201d from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on\u00a0 collaborating or working with other parties), whether during the contract or\u00a0 after the contract ends (or both).",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__No-Solicit Of Customers",
        "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Customers\" that should be reviewed by a lawyer. Details: Is a party restricted from contracting or soliciting customers or partners of the counterparty, whether during the contract or after the contract ends (or both)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Competitive Restriction Exception",
        "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__No-Solicit Of Employees",
        "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party\u2019s soliciting or hiring employees and/or contractors from the\u00a0 counterparty, whether during the contract or after the contract ends (or both)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Non-Disparagement",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Disparagement\" that should be reviewed by a lawyer. Details: Is there a requirement on a party not to disparage the counterparty?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Termination For Convenience",
        "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this\u00a0 contract without cause (solely by giving a notice and allowing a waiting\u00a0 period to expire)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Rofr/Rofo/Rofn",
        "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Change Of Control",
        "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Anti-Assignment",
        "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Revenue/Profit Sharing",
        "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or\u00a0services?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "The prices payable by Ultragenyx to Cremer for the Product (the \"Price\") shall be agreed [***] every contract year; provided, that the Price may not increase more than the [***] for such period or [***]%, whichever is higher.",
            "answer_start": 3496
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Price Restrictions",
        "question": "Highlight the parts (if any) of this contract related to \"Price Restrictions\" that should be reviewed by a lawyer. Details: Is there a restriction on the\u00a0 ability of a party to raise or reduce prices of technology, goods, or\u00a0 services provided?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Minimum Commitment",
        "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Volume Restriction",
        "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one party\u2019s use of the product/services exceeds certain threshold?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Ip Ownership Assignment",
        "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created\u00a0 by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Joint Ip Ownership",
        "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__License Grant",
        "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Non-Transferable License",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Affiliate License-Licensor",
        "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?\u00a0",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Affiliate License-Licensee",
        "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Unlimited/All-You-Can-Eat-License",
        "question": "Highlight the parts (if any) of this contract related to \"Unlimited/All-You-Can-Eat-License\" that should be reviewed by a lawyer. Details: Is there a clause granting one party an \u201centerprise,\u201d \u201call you can eat\u201d or unlimited usage license?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Irrevocable Or Perpetual License",
        "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a\u00a0 license grant that is irrevocable or perpetual?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Source Code Escrow",
        "question": "Highlight the parts (if any) of this contract related to \"Source Code Escrow\" that should be reviewed by a lawyer. Details: Is one party required to deposit its source code into escrow with a third party, which can be released to the counterparty upon the occurrence of certain events (bankruptcy,\u00a0 insolvency, etc.)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Post-Termination Services",
        "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Audit Rights",
        "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to\u00a0 audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Uncapped Liability",
        "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party\u2019s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "NEITHER PARTY MAY CLAIM AND NEITHER PARTY IS LIABLE FOR CLAIMS FOR INDIRECT DAMAGES AND LOSSES, SUCH AS SPECIAL OR CONSEQUENTIAL LOSS OR DAMAGE, ANY LOSS OF ACTUAL OR ANTICIPATED PROFIT, OR REVENUE, ANTICIPATED SAVINGS OR BUSINESS OR DAMAGE TO GOODWILL OR BRAND EQUITY, ARE EXCLUDED.",
            "answer_start": 9072
          },
          {
            "text": "Cremer's liability arising from this Agreement is limited to intentional misconduct or gross negligence.",
            "answer_start": 8744
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Cap On Liability",
        "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party\u2019s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Liquidated Damages",
        "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "In the event that the Product fails to conform to the Product Specifications, and/or GMP, Ultragenyx may reject the Product by giving written notice to Cremer within [***] days after receipt of the Product and all documentation (except such [***] day period will not apply for any latent defect).",
            "answer_start": 6032
          }
        ],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Warranty Duration",
        "question": "Highlight the parts (if any) of this contract related to \"Warranty Duration\" that should be reviewed by a lawyer. Details: What is the duration of any\u00a0 warranty against defects or errors in technology, products, or services\u00a0 provided under the contract?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Insurance",
        "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Covenant Not To Sue",
        "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty\u2019s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "ULTRAGENYXPHARMACEUTICALINC_12_23_2013-EX-10.9-SUPPLY AGREEMENT__Third Party Beneficiary",
        "question": "Highlight the parts (if any) of this contract related to \"Third Party Beneficiary\" that should be reviewed by a lawyer. Details: Is there a non-contracting party who is a beneficiary to some or all of the clauses in the contract and therefore can enforce its rights against a contracting party?",
        "is_impossible": true
      }
    ],
    "context": "Exhibit 10.9\n\nSUPPLY AGREEMENT\n\nbetween\n\nCREMER OLEO GmbH & Co KG, Glockengiesserwall 3, 20095 Hamburg,\n\nGermany\n\n\u2014 hereinafter referred to as Cremer \u2014\n\nand\n\nUltragenyx Pharmaceutical Inc, 60 Leveroni Court, Suite 200, Novato, California 94949, United States of America\n\n\u2014 hereinafter referred to as Ultragenyx \u2014\n\n\u00ad each party also referred to as a \"Party\" and jointly as the \"Parties\" -\n\nPreamble\n\nWhereas, Cremer is a producer of oleo chemical products;\n\nWhereas, Ultragenyx is a biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan diseases, to market;\n\nWhereas, the Parties desire that Cremer supplies to Ultragenyx the product Triheptanoin (hereinafter also referred to as the \"Product\") in bulk form pursuant to the terms and conditions of this Agreement;\n\nWhereas, Ultragenyx intends to process the Product into a pharmaceutical product in the meaning of Sec. 2 German Pharmaceuticals Act (Arzneimittelgesetz\u2014AMG) and to market the processed Product in the Field (as defined below) (hereinafter referred to as the \"Purpose\"); and\n\nWhereas, Ultragenyx intends to obtain regulatory approval for the processed Product as a pharmaceutical product in the meaning of Sec. 2 AMG.\n\nNow therefore, the Parties hereto agree as follows:\n\nArticle 1 Supply of Product\n\n1) Subject to the terms and conditions set forth in this Agreement Cremer shall supply Ultragenyx with the Product free from defect and meeting the product specification attached to this Agreement as Annex A (the \"Product Specifications\").\n\n2) Cremer shall supply Ultragenyx exclusively with the Product worldwide. The aforesaid exclusivity is limited to [***] (collectively, the \"Field\"). Cremer may supply the Product to other customers outside of the Field.\n\n3) Ultragenyx shall purchase the Product exclusively from Cremer.\n\n[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.\n\n1\n\n\n\n\n\nArticle 2 Orders and Delivery\n\n1) The Product will be ordered by Ultragenyx through purchase orders. Purchase orders shall be submitted in any written or electronic form or by facsimile, setting out the quantity of Product required and the date for delivery. Cremer shall give its order confirmation in writing stating the quantity and Price (as defined below). Cremer shall not be obliged to deliver the Product in the absence of a written order confirmation given to Ultragenyx.\n\n2) Delivery of the Product in bulk form by Cremer shall be EXW (Incoterms 2010), unless otherwise agreed in writing by the Parties.\n\n3) Within [***] days of execution of this Agreement, Cremer shall deliver to Ultragenyx the Master Batch Record for the Product for Ultragenyx to review.\n\n4) All Product shall be delivered with the applicable certificate of analysis and batch records for the Product delivered and an invoice for the quantity of Product delivered.\n\n5) If Ultragenyx obtains regulatory approval for the processed Product, the Parties shall enter into a separate commercial supply agreement for the Product that sets forth the forecasting and ordering mechanism for commercial supply of the Product, enablement of the manufacturing process in the event of a failure to supply, the term of such commercial supply agreement and other customary terms and conditions.\n\nArticle 3 Prices and payment\n\n1) The prices payable by Ultragenyx to Cremer for the Product (the \"Price\") shall be agreed [***] every contract year; provided, that the Price may not increase more than the [***] for such period or [***]%, whichever is higher. At the date of signing the Parties agree on a Price of \u20ac[***] per kilogram for the Product.\n\n2) If the parties cannot agree on a price for the Product by the beginning of a following contract year, Cremer may refuse to deliver the Product to Ultragenyx until the Parties agreed on a respective price.\n\n3) Payments shall be made by Ultragenyx in Euro and within [***] days after receipt of a proper invoice.\n\n4) Transfer of title with respect to any Product shall be subject to full payment and settlement of all claims Cremer may have against Ultragenyx in connection with the execution of this Agreement.\n\nArticle 4 Specification; Warranties; Cremer's Liability; Indemnification\n\n1) The Parties assume that the Product constitutes an active pharmaceutical ingredient in the meaning of Sec. 4 para. 19 AMG. Ultragenyx shall process the Product into a pharmaceutical product in the meaning of Sec. 2 AMG and market the processed Product as a pharmaceutical product in the meaning of Sec 2 AMG and to perform clinical trials. Cremer does not participate in the processing, manufacturing and marketing of the respective pharmaceutical product or in the clinical trials.\n\n[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.\n\n2\n\n\n\n\n\n2) Upon execution of this Agreement and any purchase order, Cremer shall provide Ultragenyx with following documentation regarding the Product: Certificate of Analysis and the applicants' part of the Drug Master File once compiled.\n\n3) Cremer represents and warrants that all quantities of Product delivered under the Agreement were manufactured in accordance with GMP. The Product shall be free from defects if it is within the specifications according to Annex A.\n\n4) Cremer represents and warrants that it has not received any written notice from a third party alleging that the manufacture, use or sale of the Product infringes intellectual property rights of a third party.\n\n5) Ultragenyx will perform final release of the Product. Ultragenyx may rely on the documentation provided by Cremer and Ultragenyx will not need to independently test the Product unless Ultragenyx determines such independent testing is necessary. In the event that the Product fails to conform to the Product Specifications, and/or GMP, Ultragenyx may reject the Product by giving written notice to Cremer within [***] days after receipt of the Product and all documentation (except such [***] day period will not apply for any latent defect). Within [***] days following receipt of the rejected and returned Product from Ultragenyx, Cremer will, at Ultragenyx's choice, replace such quantity of Product with Product conforming to the Product Specifications, and GMP or refund Ultragenyx the Price paid for such Product.\n\n6) Cremer does not warrant or represent that the Product is effective in a pharmaceutical way within the meaning of Sec. 4 para. 19 AMG. Cremer does not warrant or represent that the Product is safe in a pharmaceutical and pharmacological way. Cremer does not warrant or represent that the Product is suitable for the intended Purpose by Ultragenyx. Cremer is not a pharmaceutical manufacturer within the meaning of Sec. 4 para. 18 AMG. Cremer's liability in connection with the Purpose and the processing and marketing of a pharmaceutical product is excluded. No. 9 below applies.\n\n7) Except for a claim arising out of Cremer's intentional misconduct or gross negligence under this Agreement, in the event of legal proceedings being instituted against Cremer by a third party arising out of Ultragenyx's development, processing and commercialization of the Product, Ultragenyx shall indemnify and keep indemnified Cremer in full against all damages, losses, injuries, costs and expenses in connection with such legal proceedings. Cremer will inform Ultragenyx about any legal proceedings being instituted against Cremer without delay. Ultragenyx shall control the respective legal proceedings but shall not settle any claim that admits fault on behalf of Cremer without Cremer's consent (not be unreasonably withheld).\n\n[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.\n\n3\n\n\n\n\n\n8) In the event of legal proceedings being instituted against Ultragenyx by a third party arising out of Cremer's intentional misconduct or gross negligence under this Agreement, Cremer shall indemnify and keep indemnified Ultragenyx in full against all damages, losses, injuries, costs and expenses in connection with such legal proceedings. Ultragenyx will inform Cremer about any legal proceedings being instituted against Ultragenyx without delay. Cremer shall control the respective legal proceedings but shall not settle any claim without Ultragenyx's consent (not be unreasonably withheld).\n\n9) Cremer's liability arising from this Agreement is limited to intentional misconduct or gross negligence. This limitation of liability does not apply to the injury of the life, body or health of a person, to claims according to the Product Liability Act (Produkthaftungsgesetz) or any other coercive legal liability claims.\n\n10) NEITHER PARTY MAY CLAIM AND NEITHER PARTY IS LIABLE FOR CLAIMS FOR INDIRECT DAMAGES AND LOSSES, SUCH AS SPECIAL OR CONSEQUENTIAL LOSS OR DAMAGE, ANY LOSS OF ACTUAL OR ANTICIPATED PROFIT, OR REVENUE, ANTICIPATED SAVINGS OR BUSINESS OR DAMAGE TO GOODWILL OR BRAND EQUITY, ARE EXCLUDED.\n\nArticle 5 Term and Termination\n\n1) This Agreement shall become effective on the date of its execution and shall remain in force for three years (the \"Initial Term\"). Thereafter, the Agreement shall be automatically renewed for additional two year periods (each a \"Renewal Term\", the Initial Term and all Renewal Terms, the \"Term\") unless either Party notifies the other Party of its intention not to renew in writing at least three calendar months before the expiration of the then current Term.\n\n2) If a Party materially breaches an obligation under this Agreement and does not cure such breach within sixty (60) days of receiving notice of such breach from the non-breaching Party, the non-breaching Party may terminate this Agreement immediately upon written notice to the breaching Party.\n\n3) Every termination has to be in writing.\n\nArticle 6 General Terms and Conditions\n\nThe application of General Terms and Conditions of any Party is excluded.\n\nArticle 7 Product Development\n\nAt the request and expense of Ultragenyx, Cremer shall perform development work for Ultragenyx to develop new formulations of the Product. All such work shall be performed pursuant to a statement of work (including a budget) to be agreed upon by the Parties and attached as an annex to this Agreement (each, a \"Statement of Work\"). In the event that in the course of performing a Statement of Work new Product know\u00adhow and intellectual property rights may result, can be created or have been created the Parties will enter into a separate Agreement in order to define the rights and duties regarding the aforesaid know how and intellectual property rights.\n\n[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.\n\n4\n\n\n\n\n\nArticle 8 Invalidity\n\nIn the event that any individual clauses of these terms and conditions are, or shall become, invalid, this shall not affect the validity of the remaining clauses. An invalid condition shall be deemed to have been replaced by such provision which is legally valid and corresponds nearest to the economic purpose of the clause originally deemed invalid.\n\nArticle 9 Applicable Law; Modifications; Annexes; Miscellaneous\n\n1) The laws of the Federal Republic of Germany shall apply to the Agreement and any legal relations thereof, especially any purchase order, between Cremer and Ultragenyx shall be governed by that law. The law of the United Nations Conventions of the formation of Agreements for the international sale of goods (CISG) is excluded. Exclusive place of Jurisdiction is Hamburg, Germany.\n\n2) No addition or modification to this Agreement shall be valid unless made in writing and signed by the Parties.\n\n3) The Annex attached to this Agreement form an integral part of the Agreement.\n\n4) This Agreement, including the Annexes and any Statement of Work, constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all written or oral prior agreements or understandings with respect thereto except the Confidentiality Agreement between the parties dated September 26t h, 2012. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto, their successors and assigns.\n\n5) All waivers must be in writing and signed by the Party to be charged. Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of any other provision or of such provision on any other occasion.\n\n6) Each Party must deliver all notices, consents, and approvals required or permitted under this Agreement in writing to the other Party at the address specified above, by personal delivery, by certified or registered mail (postage prepaid and return receipt requested), by a nationally- recognized overnight carrier, or by facsimile transmission with electronic confirmation of transmission. Notice will be effective upon receipt or refusal of delivery. Each Party may change its address for receipt of notice by giving notice of such change to the other Party.\n\n7) This Agreement may be executed in counterparts by original signature, facsimile or PDF files, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.\n\n5\n\n\n\n\n\nHamburg, November 19t h, 2012\n\n  /s/ Thomas Kassberg   /s/ Dr. R. Stephan Ultragenyx Pharmaceutical Inc\n\n\n\nCREMER OLEO GmbH & Co KG\n\n  CREMER OLEO GmbH & Co. KG Postfach 10 11 20, D-20007 Hamburg Tel: 040/320 11-0, Telefax 320 11-400\n\n6\n\n\n\n\n\nAnnex A \u2014 Specification of the Product Trihepatanoin (Heptans\u00e4uretriglycerid)\n\nNo  Test   EP method  Limits\n\n1  [***] [***],  [***] 2  [***] [***]  [***] 3  [***] [***]  [***] 4  [***] [***]  [***] 5  [***] [***]  [***] 6  [***] [***]  [***] 7  [***] [***]  [***] 8  [***] [***]  [***] 9  [***] [***]  [***] 10  [***] [***]  [***] 11  [***] [***]  [***] 12  [***]  [***] 13  [***] [***]  [***] 18  [***] [***]  [***]\n\n[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.\n\n7"
  }
]